Abstract
Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
CNS & Neurological Disorders - Drug Targets
Title:From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction
Volume: 14 Issue: 6
Author(s): Ivan Diamond and Lina Yao
Affiliation:
Keywords: Addiction, alcohol, ALDH2, cocaine, craving, relapse.
Abstract: Pharmacologic agents for CNS disorders are often inhibitors that occupy receptors, with frequent unavoidable side effects likely due to continuous binding. This review summarizes development of a novel aldehyde dehydrogenase 2 (ALDH2) inhibitor that specifically targets unique drug related episodic surges in dopamine (DA), a pathophysiologic mechanism that appears to underlie much of drug-seeking behavior. We have synthesized highly selective novel ALDH2 inhibitors (ALDH2i) that block alcohol- and cocaine cue-induced surges in nucleus accumbens (NAc) DA and prevent reinstatement of alcohol heavy drinking, cocaine self-administration and reinstatement of cocaine relapse-like behavior. The mechanism of action of ALDH2i depends on inhibiting dopamine aldehyde (DOPAL) clearance by ALDH2, enabling unmetabolized DOPAL to condense with DA to generate tetrahydropapaveroline (THP). THP selectively inhibits the activated (phosphorylated) tyrosine hydroxylase (TH) to suppress DA synthesis. Selective inhibition of ALDH2 appears to have therapeutic potential for treating cue-induced drug relapse, a major unmet need for treating addicted subjects.
Export Options
About this article
Cite this article as:
Diamond Ivan and Yao Lina, From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529144329
DOI https://dx.doi.org/10.2174/1871527314666150529144329 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythropoietin and Oxidative Stress
Current Neurovascular Research A Structural Feature of the Non-Peptide Ligand Interactions with Mice Mu-Opioid Receptors
Current Computer-Aided Drug Design Meet the Editorial Board Member
Current Neuropharmacology Meet Our Editorial Board Member
Current Alzheimer Research Formulation Development and Evaluation of Novel Vesicular Carrier for Enhancement of Bioavailability of Poorly Soluble Drug
Pharmaceutical Nanotechnology Towards an Understanding of the Anti-Aging Mechanism of Caloric Restriction
Current Aging Science Pharmacological Aspects of Neuro-Immune Interactions
Current Pharmaceutical Design The New Era of Nutraceuticals: Beneficial Effects of Polyphenols in Various Experimental and Clinical Settings
Current Pharmaceutical Design Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets SNew Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief
Current Topics in Medicinal Chemistry Activity of γ -Secretase on Substrates Other than APP
Current Topics in Medicinal Chemistry Clinical Evaluation of Anti-Obesity Drugs
Current Drug Targets A Short Historical Survey of Developments in Amyloid Research
Protein & Peptide Letters Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Nature and Nurture: Genetic Influences and Gene-Environment Interactions in Depression
Current Psychiatry Reviews Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism New Insight into Diabetes Management: From Glycemic Index to Dietary Insulin Index
Current Diabetes Reviews Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets